Neurocrine Bioscienc
(NQ:
NBIX
)
120.17
-1.04 (-0.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
868,976
Open
122.20
Bid (Size)
112.00 (1)
Ask (Size)
123.25 (1)
Prev. Close
121.21
Today's Range
119.85 - 122.75
52wk Range
103.63 - 157.98
Shares Outstanding
100,900,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
September 05, 2024
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases.
Via
Chartmill
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
September 02, 2024
10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them.
Via
Benzinga
Performance
YTD
-8.78%
-8.78%
1 Month
-18.10%
-18.10%
3 Month
-10.79%
-10.79%
6 Month
-13.30%
-13.30%
1 Year
+9.98%
+9.98%
More News
Read More
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Why Neurocrine Biosciences Stock Was Tumbling This Week
August 30, 2024
Via
The Motley Fool
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
August 19, 2024
Via
Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
August 19, 2024
Via
Chartmill
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
August 29, 2024
Via
Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
August 29, 2024
Via
Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
August 28, 2024
Via
Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Via
Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
August 28, 2024
Via
Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
August 19, 2024
Via
Chartmill
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
August 01, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
Via
Investor's Business Daily
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Via
Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
August 22, 2024
Via
Chartmill
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
Via
Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
Via
PressReach
Exposures
Product Safety
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
July 26, 2024
Via
Chartmill
So Much For Expecting The Fed To Stick The Landing
August 04, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
NASDAQ:NBIX, a growth stock which is not overvalued.
July 26, 2024
Via
Chartmill
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
July 25, 2024
Via
Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
July 10, 2024
Via
Benzinga
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
July 05, 2024
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.